LINCOLN · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 52/100 — Quality 57 · Valuation 45 · Momentum 51
| Share price | ₹597.40 |
| Market cap | ₹1,233 Cr |
| P/E ratio | 14.0 |
| P/B ratio | 1.6 |
| ROCE | 15.0% |
| Dividend yield | 0.29% |
| Book value | ₹378.34 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹671 Cr | ₹88 Cr | 15.0% |
| 2025 | ₹623 Cr | ₹82 Cr | 16.0% |
| 2024 | ₹581 Cr | ₹93 Cr | 17.0% |
| 2023 | ₹510 Cr | ₹73 Cr | 18.0% |
| 2022 | ₹472 Cr | ₹69 Cr | 20.0% |
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporat